200 related articles for article (PubMed ID: 23868281)
1. Breath tests to phenotype drug disposition in oncology.
Opdam FL; Modak AS; Gelderblom H; Guchelaar HJ
Clin Pharmacokinet; 2013 Nov; 52(11):919-26. PubMed ID: 23868281
[TBL] [Abstract][Full Text] [Related]
2. Phenotyping drug disposition in oncology.
Opdam FL; Gelderblom H; Guchelaar HJ
Cancer Treat Rev; 2012 Oct; 38(6):715-25. PubMed ID: 22226243
[TBL] [Abstract][Full Text] [Related]
3. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil.
Mattison LK; Fourie J; Hirao Y; Koga T; Desmond RA; King JR; Shimizu T; Diasio RB
Clin Cancer Res; 2006 Jan; 12(2):549-55. PubMed ID: 16428499
[TBL] [Abstract][Full Text] [Related]
4. The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels.
Opdam FL; Dezentje VO; den Hartigh J; Modak AS; Vree R; Batman E; Smorenburg CH; Nortier JW; Gelderblom H; Guchelaar HJ
Cancer Chemother Pharmacol; 2013 Mar; 71(3):593-601. PubMed ID: 23228987
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
Meulendijks D; Henricks LM; Jacobs BAW; Aliev A; Deenen MJ; de Vries N; Rosing H; van Werkhoven E; de Boer A; Beijnen JH; Mandigers CMPW; Soesan M; Cats A; Schellens JHM
Br J Cancer; 2017 May; 116(11):1415-1424. PubMed ID: 28427087
[TBL] [Abstract][Full Text] [Related]
6. Single time point diagnostic breath tests: a review.
Modak AS
J Breath Res; 2010 Mar; 4(1):017002. PubMed ID: 21386204
[TBL] [Abstract][Full Text] [Related]
7. Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism.
Thomas HR; Ezzeldin HH; Guarcello V; Mattison LK; Fridley BL; Diasio RB
Pharmacogenet Genomics; 2007 Nov; 17(11):973-87. PubMed ID: 18075467
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
Bosch TM; Meijerman I; Beijnen JH; Schellens JH
Clin Pharmacokinet; 2006; 45(3):253-85. PubMed ID: 16509759
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test.
Michael M; Cullinane C; Hatzimihalis A; O'Kane C; Milner A; Booth R; Schlicht S; Clarke SJ; Francis P
Cancer Chemother Pharmacol; 2012 Jan; 69(1):125-35. PubMed ID: 21626050
[TBL] [Abstract][Full Text] [Related]
10. Fluoropyrimidines and DPD testing: is there truly an inexorable link?
Milano G
Eur J Cancer; 2019 May; 113():45-46. PubMed ID: 30974323
[No Abstract] [Full Text] [Related]
11. Further characterization of a ¹³C-dextromethorphan breath test for CYP2D6 phenotyping in breast cancer patients on tamoxifen therapy.
Opdam FL; Modak AS; Gelderblom H; Guchelaar HJ
J Breath Res; 2015 Apr; 9(2):026003. PubMed ID: 25891764
[TBL] [Abstract][Full Text] [Related]
12. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
Ostapowicz A; Dołegowska B
Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991
[TBL] [Abstract][Full Text] [Related]
13. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.
Jones DR; Gorski JC; Haehner BD; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1996 Oct; 60(4):374-84. PubMed ID: 8873685
[TBL] [Abstract][Full Text] [Related]
14. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
[TBL] [Abstract][Full Text] [Related]
15. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
Ogura K
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
[TBL] [Abstract][Full Text] [Related]
16. Optimizing the erythromycin breath test for use in cancer patients.
Rivory LP; Slaviero K; Seale JP; Hoskins JM; Boyer M; Beale PJ; Millward MJ; Bishop JF; Clarke SJ
Clin Cancer Res; 2000 Sep; 6(9):3480-5. PubMed ID: 10999732
[TBL] [Abstract][Full Text] [Related]
17. Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics.
Deeken JF; Figg WD; Bates SE; Sparreboom A
Anticancer Drugs; 2007 Feb; 18(2):111-26. PubMed ID: 17159598
[TBL] [Abstract][Full Text] [Related]
18. Relationships among plasma [2-(13)C]uracil concentrations, breath (13)CO(2) expiration, and dihydropyrimidine dehydrogenase (DPD) activity in the liver in normal and dpd-deficient dogs.
Inada M; Hirao Y; Koga T; Itose M; Kunizaki J; Shimizu T; Sato H
Drug Metab Dispos; 2005 Mar; 33(3):381-7. PubMed ID: 15616154
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen.
Safgren SL; Suman VJ; Kosel ML; Gilbert JA; Buhrow SA; Black JL; Northfelt DW; Modak AS; Rosen D; Ingle JN; Ames MM; Reid JM; Goetz MP
Pharmacogenet Genomics; 2015 Apr; 25(4):157-63. PubMed ID: 25714002
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.
Schadel M; Wu D; Otton SV; Kalow W; Sellers EM
J Clin Psychopharmacol; 1995 Aug; 15(4):263-9. PubMed ID: 7593709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
